Results of multicenter registry for patients with inherited factor VII deficiency in Turkey

dc.contributor.authorAkdeniz, Aydan
dc.contributor.authorUnuvar, Aysegul
dc.contributor.authorAr, Muhlis Cem
dc.contributor.authorPekpak, Esra
dc.contributor.authorAkyay, Arzu
dc.contributor.authorMehtap, Ozgur
dc.contributor.authorDemir, Ahmet Muzaffer
dc.date.accessioned2026-08-12T17:19:59Z
dc.date.issued2022
dc.departmentFırat Üniversitesi
dc.description.abstractIntroduction: Inherited factor VII (FVII) deficiency (FVIID) is the most common of inherited rare bleeding disorders. Other determinants of clinical severity apart from FVII level (FVIIL) include genetic and environmental factors. We aimed to identify the cut-off FVIILs for general and severe bleedings in patients with FVIID by using an online national registry system including clinical, laboratory, and demographic characteristics of patients. Methods: Demographic, clinical, and laboratory data of patients with FVIID extracted from the national database, constituted by the Turkish Society of Hematology, were examined. Bleeding phenotypes, general characteristics, and laboratory features were assessed in terms of FVIILs. Bleeding rates and prophylaxis during special procedures/interventions were also recorded. Results: Data from 197 patients showed that 46.2% of patients had FVIIL< 10%. Most bleeds were of mucosal origin (67.7%), and severe bleeds tended to occur in younger patients (median age: 15 (IQR:6-29)). Cut-off FVIILs for all and severe bleeds were 16.5% and 7.5%, respectively. The major reason for long-term prophylaxis was observed as central nervous system bleeding (80%). Conclusion: Our data are consistent with most of the published literature in terms of cut-off FVIIL for bleeding, as well as reasons for prophylaxis, showing both an increased severity of bleeding and younger age at diagnosis with decreasing FVIIL. However, in order to offer a classification similar to that in Hemophilia A or B, data of a larger cohort with information about environmental and genetic factors are required.
dc.identifier.doi10.1080/00365513.2021.2013524
dc.identifier.endpage36
dc.identifier.issn0036-5513
dc.identifier.issn1502-7686
dc.identifier.issue1
dc.identifier.orcid0000-0002-0332-9253
dc.identifier.orcid0000-0002-8801-7776
dc.identifier.orcid0000-0001-6078-5944
dc.identifier.orcid0000-0001-6923-1470
dc.identifier.orcid0000-0003-2143-1435
dc.identifier.orcid0000-0001-9315-8891
dc.identifier.orcid0000-0003-2701-7980
dc.identifier.pmid34915774
dc.identifier.scopus2-s2.0-85121735923
dc.identifier.scopusqualityQ3
dc.identifier.startpage28
dc.identifier.urihttps://doi.org/10.1080/00365513.2021.2013524
dc.identifier.urihttps://hdl.handle.net/11508/53400
dc.identifier.volume82
dc.identifier.wosWOS:000731213900001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofScandinavian Journal of Clinical & Laboratory Investigation
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectFactor VII
dc.subjectrare diseases
dc.subjectFVII deficiency
dc.subjecthemorrhage
dc.subjectblood coagulation disorder
dc.titleResults of multicenter registry for patients with inherited factor VII deficiency in Turkey
dc.typeArticle

Dosyalar